SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-010227
Filing Date
2024-01-18
Accepted
2024-01-18 16:26:52
Documents
14
Period of Report
2024-01-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d459979d8k.htm   iXBRL 8-K 31934
2 EX-99.1 d459979dex991.htm EX-99.1 16435
6 GRAPHIC g459979g0118225114764.jpg GRAPHIC 1643
  Complete submission text file 0001193125-24-010227.txt   187089

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikna-20240117.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikna-20240117_lab.xml EX-101.LAB 19500
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikna-20240117_pre.xml EX-101.PRE 12168
8 EXTRACTED XBRL INSTANCE DOCUMENT d459979d8k_htm.xml XML 3597
Mailing Address 50 NORTHERN AVE. BOSTON MA 02210
Business Address 50 NORTHERN AVE. BOSTON MA 02210 857-343-8292
Ikena Oncology, Inc. (Filer) CIK: 0001835579 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40287 | Film No.: 24542165
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)